Arbitel 80 mg Tablet (Telmisartan 80 mg) – ACI Limited

1. About Arbitel 80 mg (Telmisartan 80 mg)

Arbitel 80 mg Tablet contains Telmisartan 80 mg, the maximum recommended monotherapy dose of this Angiotensin II Receptor Blocker (ARB), manufactured by ACI Limited, Bangladesh. At 80 mg, telmisartan provides its maximum antihypertensive effect and is the evidence-based dose for cardiovascular risk reduction (established in the landmark ONTARGET trial). It is used for patients with moderate-to-severe hypertension, high cardiovascular risk, or those requiring maximal RAAS blockade for optimal renal protection in diabetic nephropathy.

Telmisartan 80 mg provides superior blood pressure reduction compared to lower doses — approximately 15–20 mmHg systolic and 8–12 mmHg diastolic reduction compared to placebo in controlled trials. Its exceptional 24-hour half-life ensures continuous antihypertensive effect with once-daily dosing, including critical coverage of the early morning cardiovascular risk period (6am–10am).

2. Mechanism of Action

Telmisartan is a potent, selective, insurmountable (non-competitive) AT1 receptor antagonist — it binds AT1 receptors with high affinity and a slow dissociation rate, providing prolonged receptor occupancy beyond its plasma half-life. This explains its sustained 24-hour antihypertensive effect. By blocking AT1 receptors: peripheral resistance decreases (vasodilation), aldosterone secretion is reduced (less sodium/water retention), sympathetic activation is blunted, and cardiac/vascular/renal remodelling is inhibited. Additionally, telmisartan partially activates PPAR-γ receptors — at clinically relevant 80 mg doses — contributing to improved insulin sensitivity and favourable lipid effects, benefits not seen with most other ARBs.

3. Indications

• Hypertension (moderate-to-severe): Maximum monotherapy dose for patients not at target on 40 mg
• Cardiovascular Risk Reduction: 80 mg is the ONTARGET evidence dose — reduces MI, stroke, CV death in high-risk patients with established CAD, cerebrovascular disease, peripheral arterial disease, or type 2 diabetes with end-organ damage
• Diabetic Nephropathy: Maximum renoprotective dose — reduces proteinuria and slows CKD progression
• Resistant Hypertension: Backbone of combination regimens (+ amlodipine, + HCTZ)
• Left Ventricular Hypertrophy regression

4. Dosage and Administration

Hypertension: 80 mg once daily — use when 40 mg is insufficient after 4–8 weeks. Maximum dose 80 mg/day.

Cardiovascular risk reduction (ONTARGET dose): 80 mg once daily.

Hepatic impairment: Maximum 40 mg/day in mild-moderate hepatic impairment (reduced biliary elimination). Contraindicated in severe hepatic impairment.

Take at the same time daily, with or without food. Telmisartan is food-independent. Do not crush or chew.

5. Contraindications

• Hypersensitivity to telmisartan
• Pregnancy (all trimesters — teratogenic/fetotoxic)
• Severe hepatic impairment / cholestasis / biliary obstructive disorders
• Concurrent aliskiren in patients with diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Absolute contraindication. Foetal renal dysplasia, oligohydramnios, skull hypoplasia, and neonatal renal failure documented with RAAS blockers. Immediately stop and switch to methyldopa, labetalol, or nifedipine if pregnancy confirmed.

First-dose and volume depletion hypotension: At 80 mg, hypotension risk is higher in volume-depleted patients. Do not initiate at 80 mg in patients with volume depletion (on diuretics, restricted salt, diarrhoea). Start at 20–40 mg, then titrate.

Renal function / hyperkalaemia: Monitor K+ and creatinine especially in CKD, diabetes, and when combined with other K+-sparing agents. Can cause acute kidney injury in bilateral renal artery stenosis.

Hepatic impairment: Biliary elimination pathway. Cap at 40 mg/day in hepatic impairment. Contraindicated if severe.

7. Side Effects

Common: Dizziness (postural), headache, fatigue, back pain, upper respiratory tract infections, diarrhoea, nausea.

Uncommon: Hyperkalaemia, orthostatic hypotension (more likely at 80 mg), elevated creatinine, anaemia.

Rare: Angioedema (rare — much less frequent than ACE inhibitors), hepatic dysfunction, thrombocytopenia.

No cough: Telmisartan does not cause dry cough — key advantage in Asian populations where ACE inhibitor cough rates reach 20–30%.

8. Drug Interactions

• Diuretics/antihypertensives: Additive hypotension — initiate at 40 mg, not 80 mg
• NSAIDs: Reduce antihypertensive efficacy and increase renal impairment risk
• Digoxin: Telmisartan raises digoxin Cmax by ~50% — monitor digoxin levels
• Lithium: Increased lithium toxicity — monitor levels
• K+-sparing diuretics/supplements: Hyperkalaemia risk
• ACE inhibitors (dual RAAS): Avoid — ONTARGET showed no additional benefit but doubled renal/hypotension complications

9. ONTARGET Trial — Telmisartan 80 mg Evidence

The ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) — 25,620 patients with established cardiovascular disease or high-risk T2DM — demonstrated that telmisartan 80 mg once daily was non-inferior to ramipril 10 mg for the composite endpoint of cardiovascular death, MI, stroke, and hospitalisation for heart failure. Telmisartan had significantly fewer side effects: 1.1% vs 4.2% cough, and less angioedema than ramipril. This landmark trial established telmisartan 80 mg as a first-line ARB for high-cardiovascular-risk patients — particularly for those who develop ACE inhibitor cough (highly prevalent in Bangladeshi/South Asian patients).

10. Pharmacokinetics

Absolute bioavailability at 80 mg: ~58%. Protein binding >99.5%. Hepatic glucuronidation to an inactive acyl glucuronide; biliary/faecal excretion ~97%. t½: ~24 hours — longest among available ARBs. Tmax: ~0.5–1.0 h. No active metabolites. No renal dose adjustment — biliary elimination means no accumulation even in dialysis patients.

11. Telmisartan 80 mg in Diabetic Hypertension

The combination of hypertension and T2DM dramatically increases cardiovascular and renal risk. Telmisartan 80 mg addresses both: it lowers BP to target (<130/80 mmHg for T2DM with nephropathy per ADA/BADAS guidelines) and provides RAAS-mediated renoprotection. Its PPAR-γ partial agonist activity at 80 mg dose may provide additional metabolic benefits including improved insulin sensitivity and modest favourable lipid effects — supporting its preference over other ARBs in metabolically active diabetic patients. No dose adjustment is needed in diabetic CKD, making it safe across all stages of nephropathy.

12. ACI Limited Arbitel Range

The complete Arbitel range: Arbitel 20 mg (initiation/elderly), Arbitel 40 mg (standard starting dose), Arbitel 80 mg (maximum dose/CV risk reduction), Arbitel AM 5+40 mg / 5+80 mg (+ Amlodipine CCB), Arbitel Plus 40+12.5 mg / 80+12.5 mg (+ Hydrochlorothiazide). This range enables step-up from initiation to maximum combination therapy within a single brand.

13. Storage

• Store below 30°C, cool, dry, protected from moisture and light
• Keep in original blister. Keep out of reach of children.
• Do not use after expiry date.

Frequently Asked Questions (FAQ)

Q1: What makes Telmisartan 80 mg (Arbitel 80) the preferred dose for cardiovascular risk reduction?

The ONTARGET trial — the largest ARB cardiovascular outcomes trial (25,620 patients) — used telmisartan 80 mg once daily and showed it was as effective as ramipril (ACE inhibitor) at reducing heart attacks, strokes, and cardiovascular death in high-risk patients. Crucially, telmisartan caused far less cough (1.1% vs 4.2%) and less angioedema. Since 20–30% of South Asian/Bangladeshi patients develop ACE-inhibitor-induced cough, telmisartan 80 mg is the go-to switch option without sacrificing cardiovascular protection.

Q2: Why is Telmisartan 80 mg preferred over 40 mg for some patients?

For patients with moderate-to-severe hypertension not controlled on 40 mg, or those requiring maximum renoprotection (diabetic nephropathy with significant proteinuria), or those with high cardiovascular risk (established CAD, stroke, T2DM with end-organ damage), 80 mg provides meaningfully greater BP reduction (∼3–5 mmHg additional systolic) and is the dose demonstrated to reduce cardiovascular events in ONTARGET. The 80 mg dose also achieves higher PPAR-γ activation, potentially benefiting insulin sensitivity in T2DM patients. Titration from 40 mg to 80 mg is the standard step-up in clinical practice.

Q3: Can Arbitel 80 mg be combined with amlodipine or a diuretic?

Yes — telmisartan 80 mg is frequently combined with other antihypertensives for better BP control. ACI Limited offers ready-made combinations: Arbitel AM 5+80 mg (telmisartan 80 mg + amlodipine 5 mg) for patients needing ARB + CCB combination, and Arbitel Plus 80+12.5 mg (telmisartan 80 mg + hydrochlorothiazide 12.5 mg) for those needing ARB + diuretic. Triple therapy (ARB + CCB + diuretic) is standard for resistant hypertension. Do not combine with another ARB, ACE inhibitor, or aliskiren (dual RAAS).

Q4: Is Telmisartan (Arbitel) safe for long-term use?

Yes — telmisartan is one of the best-studied ARBs with a well-established long-term safety profile from large trials including ONTARGET (up to 5.5 years). It does not cause cumulative toxicity and is safe for indefinite use in hypertensive and high-CV-risk patients. Annual monitoring of blood pressure, renal function (eGFR/creatinine), serum potassium, and albuminuria (in diabetic patients) is recommended. Patients with T2DM and hypertension on telmisartan should have these parameters checked at least annually, or more frequently if CKD is present or other nephrotoxic medications are co-prescribed.